FY2024 EPS Estimates for Cerus Boosted by Cantor Fitzgerald

Cerus Co. (NASDAQ:CERS) – Stock analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for shares of Cerus in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the biotechnology company will post earnings per share of ($0.11) for the year, up from their previous forecast of ($0.12). The consensus estimate for Cerus’ current full-year earnings is ($0.12) per share. Cantor Fitzgerald also issued estimates for Cerus’ FY2025 earnings at ($0.06) EPS.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $46.02 million during the quarter, compared to the consensus estimate of $44.10 million. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%. During the same period last year, the firm earned ($0.03) EPS.

Separately, Stifel Nicolaus lowered their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th.

Cerus Stock Performance

Cerus stock opened at $1.85 on Thursday. The firm’s fifty day moving average price is $1.71 and its 200-day moving average price is $1.89. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The stock has a market cap of $343.57 million, a P/E ratio of -16.82 and a beta of 1.27. Cerus has a fifty-two week low of $1.38 and a fifty-two week high of $2.59.

Insider Buying and Selling

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the sale, the director now owns 162,133 shares of the company’s stock, valued at $288,596.74. This trade represents a 10.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cerus

Large investors have recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Cerus in the 4th quarter worth $29,000. Creative Planning grew its holdings in Cerus by 51.3% in the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 8,411 shares during the last quarter. PCA Investment Advisory Services Inc. bought a new stake in Cerus in the 4th quarter worth $46,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in Cerus by 38.4% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 9,737 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Cerus in the 3rd quarter worth $71,000. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.